

References For Hormones, Testing and HRT

Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer, D A Kossman et al, J Appl Physiol (1985). 2011 Dec;111(6):1687-93

The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women, Kenna Stephenson et al, Int J Pharm Compd. Jan-Feb 2013;17(1):74-85

- Schiffer L, et al. Intracrine androgen biosynthesis, metabolism and action revisited. Mol Cell Endocrinol. 2018; 465: 4-26.
- Schiffer L, et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. J Steroid Biochem Mol Biol. 2019; 194: 105439.
- Newman M, et al. Evaluating urinary estrogen and progesterone metabolites using dried filter paper samples and gas chromatography with tandem mass spectrometry (GC-MS/MS). BMC Chem. 2019; 13(1): 20.
- Newman M, et al. Dried urine and salivary profiling for complete assessment of cortisol and cortisol metabolites. J Clin Transl Endocrinol. 2020; 22: 100243.
- Newman M, Curran DA. Reliability of a dried urine test for comprehensive assessment of urine hormones and metabolites. BMC Chem. 2021; 15(1): 18.

- Moyer DL, et al. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril. 1993; 59(5): 992-997.
- Gillet JY, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas.1994; 19(2): 103-115.
- The PEPI Writing Group. Effects of Hormone Replacement Therapy on Endometrial Histology in Postmenopausal Women. The Postmenopausal Estrogen/Progestin Intervention Trial (PEPI). JAMA. 1996; 275(5): 370-375.
- Ross D, et al. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol. 1997; 177(4): 937-941.
- De Ziegler D, et al. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod. 2000; 15(Suppl 1): 149-158.

- Wren BG, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. *Climacteric*. 2000; 3(3): 155-160.
- Leonetti HB, et al. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. *Fertil Steril*. 2003; 79(1): 221-222.
- Leonetti HB, et al. Transdermal progesterone cream as an alternative progestin in hormone therapy. *Altern Ther Health Med*. 2005; 11(6): 36-38.
- Vashisht A, et al. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regimen. *BJOG*. 2005; 112(10): 1402-1406.
- Di Carlo C, et al. Transdermal Estradiol and Oral or Vaginal Natural Progesterone: Bleeding Patterns. *Climacteric*. 2010; 13(5): 442-446.
- Ruan X, Mueck AO. Systemic progesterone therapy—Oral, vaginal, injections and even transdermal? *Maturitas*. 2014; 79(3): 248-255.
- Stute P, et al. The impact of micronized progesterone on the endometrium: A systematic review. *Climacteric*. 2016; 19(4): 316-328.
- Cobin RH, Goodman NF. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause – 2017 Update. *Endocr Pract*. 2017; 23(7): 869-881.
- Pinkerton JAV, et al. The 2017 hormone therapy position statement of the North American Menopause Society. *Menopause*. 2017; 24(7): 728-753.
- Mirkin S, et al. Endometrial safety and bleeding profile of a 17 β -estradiol/progesterone oral softgel capsule (TX-001HR). *Menopause*. 2020; 27(4): 000-000.
- Prior JC, et al. Spinal Bone Loss and Ovulatory Disturbances. *N Engl J Med*. 1990; 323(18): 1221-1227.
- Li D, et al. Negative Spinal Bone Mineral Density Changes and Subclinical Ovulatory Disturbances – Prospective Data in Healthy Premenopausal Women with Regular Menstrual Cycles. *Epidemiol Rev*. 2014; 36: 137-147.
- Prior JC, et al. Ovulation Prevalence in Women with Spontaneous Normal-Length Menstrual Cycles – A Population-Based Cohort from HUNT3, Norway. *PloS One*. 2015; 10(8): e0134473.

- Prior JC, et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systemic review and meta-analysis of controlled trials with direct randomization. *J Musculoskelet Neuronal Interact.* 2017; 17(3): 146-154.
- Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. *Climacteric.* 2018; 21(4), 366-374.
- Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms - a placebo-controlled randomized trial in healthy postmenopausal women. *Menopause.* 2012; 19(8): 1-8.
- Prior JC, Hitchcock CL. Progesterone for hot flush and night sweat treatment – effectiveness for severe vasomotor symptoms and lack of withdrawal rebound. *Gynecol Endocrinol.* 2012; 28(Suppl 2): 7-11.
- Prior JC. Progesterone for treatment of symptomatic menopausal women. *Climacteric.* 2018; 21(4): 358-365.
- Gubbels MR. Sex, the aging immune system, and chronic disease. *Cell Immunol.* 2015; 294(2): 102-110.
- Gubbels MR, et al. The Confluence of Sex Hormones and Aging on Immunity. *Front Immunol* 2018; 9: 1269.
- Mauvais-Jarvis F, et al. Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes. *Endocrinology.* 2020; 161(9): bqaa127.
- de Lignières B, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. *Climacteric.* 2002; 5(4): 332-340.
- Fournier A, et al. Breast Cancer Risk in Relation to Different Types of Hormone Replacement Therapy in the E3N-EPIC Cohort. *Int J Cancer.* 2005; 114: 448-454.
- Espie M, et al. Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phase. *Gynecol Endocrinol.* 2007; 23(7): 391-397.

- Fournier A, et al. Unequal risk for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat.* 2008; 107(1): 103-111.
- Stute P, et al. The impact of micronized progesterone on breast cancer risk: A systematic review. *Climacteric.* 2017; 21(2): 111-122.
- Honisett SY, et al. Progesterone does not influence vascular function in postmenopausal women. *J Hypertens.* 2003; 21(6): 1145-1149.
- Canonico M, et al. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women. Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study. *Circulation.* 2007; 115(7): 840-845.
- Canonico M, et al. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. *Maturitas.* 2011; 70(4): 354-360.
- Prior JC, et al. Progesterone Therapy, Endothelial Function and Cardiovascular Risk Factors: A 3-Month Randomized, Placebo-Controlled Trial in Healthy Early Postmenopausal Women. *PLoS One.* 2014; 9(1): e84698.
- Berent-Spillson A, et al. Distinctive cognitive effects of estrogen and progesterone in menopausal women. *Psychoneuroendocrinology.* (2015); 59: 25-36.
- Barros LA, et al. The role of progesterone in memory: An overview of three decades. *Neurosci Biobehav Rev.* 2015; 49: 193–204.
- Henderson VW. Progesterone and human cognition. *Climacteric.* 2018; 21(4): 333-340.
- Guennoun R. Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant. *Int J Mol Sci.* 2020; 21(15): 5271.
- Goodman MP. Are all estrogens created equal? A review of oral vs transdermal therapy. *J Womens Health (Larchmt).* 2012; 21(2): 161-169.

- Sood R, et al. Prescribing menopausal hormone therapy: an evidenced base approach. *Int J Womens Health*. 2014; 6: 47-57.
 - Stuenkel CA, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2015; 100(11): 3975-4011.
 - Beck KL, et al. Transdermal estrogens in the changing landscape of hormone replacement therapy. *Postgrad Med*. 2017; 129(6): 632-636.
 - L'Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol and progesterone) are optimal. *Climacteric*. 2017; 20(4): 331-338.
 - Pinkerton JAV, et al. The 2017 hormone therapy position statement of the North American Menopause Society. *Menopause*. 2017; 24(7): 728-753.
 - Cobin RH, Goodman NF. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause – 2017 Update. *Endocr Pract*. 2017; 23(7): 869-881.
-
- Archer DF, for the EstroGel Study Group. Percutaneous 17 β -estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. *Menopause*. 2003; 10(6): 516-521.
 - Sood R, et al. Prescribing menopausal hormone therapy: an evidenced base approach. *Int J Womens Health*. 2014; 6: 47-57.
 - Biglia N, et al. Vasomotor symptoms in menopause: a marker for cardiovascular risk and other chronic diseases? *Climacteric*. 2017; 20(4): 306-312.
 - Santoro N, et al. Longitudinal Changes in Menopausal Symptoms Comparing Women Randomized to Low- Dose Oral Conjugated Estrogen or Transdermal Estradiol Plus Micronized Progesterone Versus Placebo. *Menopause*. 2017; 24(3): 238-246.
 - Delamater L, Santoro N. Management of Perimenopause. *Clin Obstet Gynecol*. 2018; 61(3): 419-432.
 - Bachmann GA, et al. Lowest Effective Transdermal 17 β -Estradiol Dose for Relief of Hot Flashes in Postmenopausal Women: A Randomized Controlled Trial. *Obstet Gynecol*. 2007; 110(4): 771-779.
 - Corbelli J, et al. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. *Menopause*. 2015; 22(1): 114-121.
 - Diem S, et al. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. *Menopause*. 2006. 13(1): 130-138.

- Simon JA, et al. Low Dose of Transdermal Estradiol Gel for Treatment of Symptomatic Postmenopausal Women. A Randomized Controlled Trial. *Obstet Gynecol.* 2007; 109(3): 588-596.
 - Gupta P, et al. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. *Menopause.* 2008; 15(1): 94-97.
 - Bachmann GA, et al. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. *Menopause.* 2009; 16(5): 877-882.
 - Archer DF, et al. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. *Menopause.* 2012; 19(6): 622-629.
 - Faubion SS, et al. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. *Mayo Clin Proc.* 2017; 92(12): 1842-1849.
 - Crandall CJ. Treatment of Vulvovaginal Atrophy. *JAMA.* Published online September 26, 2019. doi:10.1001/jama.2019.15100.
 - Faubion SS, et al. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. *Menopause.* 2020; 27(9): 976-992.
-
- Weiss SR, et al. A Randomized Controlled Trial of Four Doses of Transdermal Estradiol for Preventing Postmenopausal Bone Loss. *Obstet Gynecol.* 1999; 94(3): 330-336.
 - Notelovitz M, et al. Effectiveness of ALORA estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. *Menopause.* 2002; 9(5): 343-353.
 - Ettinger B, et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial. *Obstet Gynecol.* 2004; 104(3): 443-451.
 - Yang TS, et al. A clinical trail of 3 Doses of Transdermal 17 β -Estradiol for Preventing Postmenopausal Bone Loss: A Preliminary Study. *J Chin Med Assoc.* 2007; 70(5): 200-206.
 - Bertonazzi A, et al. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis. *Womens Health.* 2015; 11(6): 815–824.
 - von Mach-Szczypiński J. New aspects of postmenopausal osteoporosis treatment with micronized estradiol and progesterone. *Ginekol Pol.* 2016; 87(11): 739–744.
 - Levin VA, et al. Estrogen therapy for osteoporosis in the modern era. *Osteoporos Int.* 2018; 29(5):1049-1055.

- Naunton M, et al. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. *Menopause*. 2006; 13(3): 517-527.
- Greendale GA, et al. Postmenopausal Hormone Therapy and Change in Mammographic Density. *J Natl Cancer Inst*. 2003; 95(1): 30-37.
- Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2003; 362(9382): 419-427.
- Speroff L. The Million Women Study and breast cancer. *Maturitas*. 2003; 46(1): 1-6.
- Grady D, et al. Effect of ultra-low-dose transdermal estrogen on breast density in postmenopausal women. *Menopause*. 2007; 14(3): 301-396.
- Fournier A, et al. Unequal risk for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat*. 2008; 107(1): 103-111.
- Mikkola TS, et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. *Menopause*. 2016; 23(11): 1199-1203.
- Roehm E. A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. *Obstet Gynecol Int*. 2015; 2015: 1-10.
- Chester RC, et al. What the Women's Health Initiative has taught us about menopausal hormone therapy. *Clin Cardiol*. 2018; 41(2): 247-252.
- Hodis HN, et al. Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials? *Climacteric*. 2018; 21(6): 521-528.
- Falk RT, et al. Estrogen metabolism in menopausal hormone users in the Women's Health Initiative Observational Study: Does it differ between estrogen and progestin and estrogen alone? *Int J Cancer*. 2019; 144(4): 730-734.
- Shufelt C, et al. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from WHI observational studies. *Menopause*. 2018; 25(9): 985-991.
- Chlebowski RT, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. *JAMA*. 2020; 324(4): 369-380.

- Mueck AO, Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. *Climacteric*. 2012; 15(Suppl 1): 11-17.
 - Schierbeck LL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. *BMJ*. 2012; 345: e6409: 1-11.
 - Manson JE, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. *JAMA*. 2013; 310(13): 1353-1358.
 - Mikkola TS, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. *Menopause*. 2015; 22(9): 976-983.
 - Hodis HN, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. *N Engl J Med*. 2016; 374(13): 1221-1231.
 - Bezwada P, et al. The Effect of Transdermal Estrogen Patch Use on Cardiovascular Outcomes: A systemic Review. *J Womens Health (Larchmt)*. 2017; 26(12): 1319-1325.
 - Mikkola TS, et al. New evidence for cardiac benefits of postmenopausal hormone therapy. *Climacteric*. 2017; 20(1): 5-10.
-
- Naftolin F, et al. Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment [version 1; peer review: 3 approved]. *F1000Research*. 2019; 8 (F1000 Faculty Rev): 1576.
 - Miller VM, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? *Menopause*. 2019; 26(9): 000-000. DOI: 10.1097/GME.0000000000001326.
 - Sriprasert I, et al. Differential Effects of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause. *J Clin Endocrinol Metab*. 2019; 104(2): 293-300.
-
- Asthana S, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. *Psychoneuroendocrinology*. 1999; 24(6): 657-677.
 - Asthana S, et al. High-dose estradiol improves cognition for women with AD. Results of a randomized study. *Neurology*. 2001; 57(4): 605-612.

- Joffe H, et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. *Menopause*. 2006; 13(3): 411-422.
 - Yaffe, K, et al. Effects of Ultra-Low-Dose Transdermal Estradiol on Cognition and Health-Related Quality of Life. *Arch Neurol*. 2006; 63(7): 945-950.
 - Tschanz JT, et al. The Cache County Study on Memory in Aging: Factors Affecting Risk of Alzheimer's disease and its Progression After Onset. *Int Rev Psychiatry*. 2013; 25(6): 673-685.
 - Maki PM. The Critical Window Hypothesis of Hormone Therapy and Cognition: A scientific Update on Clinical Studies. *Menopause*. 2013; 20(6): 695-709.
-
- Fischer B, et al. Effects of Hormone Therapy on Cognition and Mood. *Fertil Steril*. 2014; 101(4): 898-904.
 - McCarrey AC, Resnick SM. Postmenopausal hormone therapy and cognition. *Hum Behav*. 2015; 74: 167-172.
 - Henderson VM, et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. *Neurology*. 2016; 87(7): 1-25.
 - Uchoa MF, et al. Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors. *Front Neuroendocrinol*. 2016; 43: 60-82.
 - Gurvich C, et al. Sex Differences and the Influence of Sex Hormones on Cognition through Adulthood and the Aging Process. *Brain Sci*. 2018; 8(9): 1-14.
 - Matyi JM, et al. Lifetime estrogen exposure and cognition in late life: The Cache County Study. *Menopause*. 2019; 26(12): 1366-1374.
 - Russell JK, et al. The Role of Estrogen in Brain and Cognitive Aging. *Neurotherapeutics*. 2019; 16(3): 649-665.
 - Khadilkar SV, Patil VA. Sex Hormones and Cognition: Where Do We Stand? *J Obstet Gynaecol India*. 2019; 69(4): 303-312.
-
- Savolainen-Peltonen H, et al. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. *BMJ*. 2019; 364: 1665.
 - Gava G, et al. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopausal Hormone Therapy. *Medicina (Kaunas)*. 2019; 55(10): 668.
 - Pertesi S, et al. Menopause, cognition and dementia – A review. *Post Reprod Health*. 2019; 25(4): 200-206.

- Uddin S, et al. Estrogen Signaling in Alzheimer's Disease: Molecular Insights and Therapeutic Targets for Alzheimer's Dementia. *Mol Neurobiol.* 2020; 57(6): 2654-2670.
- Zeydan B, et al. Sleep quality and cortical amyloid- β deposition in postmenopausal women of the Kronos early estrogen prevention study. *Neuroreport.* 2021; 32(4): 326-331.
- Davis SR, et al. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas.* 1995; 21(3): 227-236.
- Shifren JL, et al. Transdermal Testosterone Treatment In Women with Impaired Sexual Function After Oophorectomy. *N Engl J Med.* 2000; 343(10): 682-688.
- Worboys S, et al. Evidence That Parenteral Testosterone Therapy May Improve Endothelial-Dependent and -Independent Vasodilation in Postmenopausal Women Already Receiving Estrogen. *J Clin Endocrinol Metab.* 2001; 86(1): 158-161.
- Goldstat R, et al. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause.* 2003; 10(5): 390-398.
- Dimitrakakis C, et al. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause.* 2004; 11(5): 531-535.
- Nathorst-Böös J, et al. Treatment with percutaneous testosterone gel in postmenopausal women with decreased libido – effects on sexuality and psychological general well-being. *Maturitas.* 2006; 53(1): 11-18.
- El-Hage G, et al. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. *Climacteric.* 2007; 10(4): 335-343.
- Davis SR, et al. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. *N Engl J Med.* 2008; 359(19): 2005-2017.
- Panay N, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. *Climacteric.* 2010; 13(2): 121-131.
- Rariy CM, et al. Higher Serum Free Testosterone Concentration in Older Women Is associated With Greater Bone Mineral Density, Lean Body Mass, and Total Fat Mass: The Cardiovascular Health Study. *J Clin Endocrinol Metab.* 2011; 96(4): 989-996.
- Glaser R, et al. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). *Maturitas.* 2011; 68(4): 355-361.

- Glaser R, et al. Testosterone implants in women: Pharmacological dosing for a physiologic effect. *Maturitas*. 2013; 74(2): 179-184.
 - Glaser R, Dimitrakakis G. Testosterone therapy in women: Myths and misconceptions. *Maturitas*. 2013; 74(3): 230-234.
 - Glaser R, Dimitrakakis C. Testosterone and breast cancer. *Maturitas*. 2015; 82(3): 291-295.
-
- Davis SR, Wahlin-Jacobsen S. Testosterone in women—the clinical significance. *Lancet Diabetes Endocrinol*. 2015; 3(12): 980-992.
 - Islam RM, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. *Lancet Diabetes Endocrinol*. 2019 Oct;7(10):754-766.
 - Skiba MA, et al. Androgens During the Reproductive Years: What is Normal for Women? *J Clin Endocrinol Metab*. 2019; 104(11): 5382-5392.
 - Glaser RL, et al. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. *BMC Cancer*. 2019; 19(1): 1271.
 - Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. *J Clin Endocrinol Metab*. 2019; 104(10): 4660–4666.
 - Parish SJ, et al. International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder. *J Sex Med*. 2021; 18(5): 849-867.
-
- Urman B, et al. Elevated Serum Testosterone, Hirsutism, and Virilism Associated with Combined Androgen-Estrogen Hormone Replacement Therapy. *Obstet Gynecol*. 1991; 77(4): E595-598.
Testosterone IM 69mg/month
 - Goldstat R, et al. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause*. 2003; 10(5): 390-398. 10mg Cream
 - Nathorst-Böös J, et al. Percutaneous administration of testosterone gel in postmenopausal women – a pharmacological study. *Gynecol Endocrinol*. 2005; 20(5): 243-248. 10-30mg Gel
 - Barton DL, et al. Randomized Controlled Trial to Evaluate Transdermal Testosterone in Female Cancer Survivors With Decreased Libido; North Central Cancer Treatment Group Protocol N02C3. *J Natl Cancer Inst*. 2007; 99(9): 672-679. 10mg Cream
 - El-Hage G, et al. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. *Climacteric*. 2007; 10(4): 335-343. 10mg Cream

- Davis S, et al. Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women. *Ann Intern Med.* 2008; 148(8): 569-577. 3.0, 4.5, 9.0mg Spray
- Waldman T, et al. Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder. *Clinical Investigation.* 2012; 2(4): 423-432. Review article "High androgen levels have not been reported with transdermal testosterone."
- Kim C, et al. Ovarian Features after 2 Weeks, 3 Weeks and 4 Weeks Transdermal Testosterone Gel Treatment and Their Associated Effect on IVF Outcomes in Poor Responders. *Dev Reprod.* 2014; 18(3): 145-152. 12.5mg Gel
- Pelusi C, et al. Effects of Three Different Testosterone Formulations in Female-to-Male Transsexual Persons. *J Sex Med.* 2014; 11(12): 3002-3011. Testoviron depot 100mg IM/10-days, T gel 50mg/d, or T undecanoate 1000mg IM Q6 weeks x 6 weeks, then 1000mg IM Q12-weeks
- Smith GI, et al. Systemic Delivery of Estradiol, but not Testosterone or Progesterone, Alters Very Low Density Lipoprotein-Triglyceride Kinetics in Postmenopausal Women. *J Clin Endocrinol Metab.* 2014; 99(7): E1306- 1310. 12.5mg Gel
- Chaikittisilpa S, et al. Efficacy of oral estrogen plus testosterone gel to improve sexual function in postmenopausal women. *Climacteric.* 2019; 22(5): 460-465. 50mg Gel Weekly